Information  X 
Enter a valid email address

Dr. Martens PLC (DOCS)

  Print   

Monday 12 July, 2021

Dr. Martens PLC

Prior year quarterly revenue figures

RNS Number : 9127E
Dr. Martens PLC
12 July 2021
 

12 July 2021

 

Dr. Martens plc

 

Publication of prior year quarterly revenue figures

 

In order to assist in understanding future relative performance, Dr. Martens plc today provides prior year quarterly revenue figures for the year ending 31 March 2021 (FY21):

 


Q1

Q2

Q3

Q4

Group revenue (£m)

97.0

221.2

275.6

179.2

% yoy change (reported)

(14%)

42%

9%

19%

% yoy change (constant currency)

(14%)

43%

9%

23%

 

 

We will announce our Q1 FY22 trading statement on 29 July 2021.

 

 

Enquiries:

 

Investors and analysts

Bethany Barnes, Director of Investor Relations

+44 7825 187465

[email protected]

 

 

 

About Dr. Martens plc:

 

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

 

The Company successfully listed on the main market of the London Stock Exchange in January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUUVWRANUBARR

a d v e r t i s e m e n t